Search Results - "Ketchum, Fred B."

Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes by Erickson, Claire M., Ketchum, Fred B., Basche, Kristin E., Chin, Nathaniel A., Eveler, Marcella L., Clark, Lindsay R.

“…Introduction Recruitment and retention pose a significant challenge to Alzheimer's disease (AD) research. Returning AD biomarker results to participants has…”
Get full text

The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research by Ketchum, Fred B, Chin, Nathaniel A, Erickson, Claire, Lambrou, Nickolas H, Basche, Kristin, Gleason, Carey E, Clark, Lindsay

“…In the asymptomatic "preclinical" phase of Alzheimer's disease (AD), abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker…”
Get full text

Solomon Carter Fuller: Alzheimer's contemporary and American pioneer by Ketchum, Fred B.

Get full text

Alzheimer's disease biomarkers in Black and non‐Hispanic White cohorts: A contextualized review of the evidence by Gleason, Carey E., Zuelsdorff, Megan, Gooding, Diane C., Kind, Amy J. H., Johnson, Adrienne L., James, Taryn T., Lambrou, Nickolas H., Wyman, Mary F., Ketchum, Fred B., Gee, Alexander, Johnson, Sterling C., Bendlin, Barbara B., Zetterberg, Henrik

“…Black Americans are disproportionately affected by dementia. To expand our understanding of mechanisms of this disparity, we look to Alzheimer's disease (AD)…”
Get full text

Pathways of care: a qualitative study of barriers and facilitators to engaging dementia care among underserved and minority populations in the US and Germany by Ketchum, Fred B., Monsees, Jessica, Kim, Alice J., Schmachtenberg, Tim, Kind, Amy, Shah, Manish, Hoffmann, Wolfgang, Thyrian, Jochen René, Gilmore-Bykovskyi, Andrea

“…To identify barriers and facilitators to the use of formal dementia services among underserved and minority groups (UMG) in the United States and Germany…”
Get full text

Commentary: Care, Choice, and the Ethical Imagination by Ketchum, Fred B.

Get full text

What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis by Ketchum, Fred B, Erickson, Claire M, Chin, Nathaniel A, Gleason, Carey E, Lambrou, Nickolas H, Benton, Susan Flowers, Clark, Lindsay R

“…Alzheimer's disease (AD) begins with an asymptomatic "preclinical" phase, in which abnormal biomarkers indicate risk for developing cognitive impairment…”
Get more information

Concerns with the new biological research criteria for synucleinopathy by Boeve, Bradley F, Davis, Albert A, Ju, Yo-El, Kantarci, Kejal, Singer, Wolfgang, Videnovic, Aleks, Avidan, Alon, Bliwise, Don, Boeve, Brad, Campbell, Meghan, Criswell, Susan, Davis, Albert “Gus”, Duff, Kevin, Ehgoetz-Martens, Kaylena, Elliott, Jon, Ferman, Tanis, Fields, Julie, Forsberg, Leah, Gagnon, Jean-Francois, Gan-Or, Ziv, Howell, Mike, Hu, Michele, Hu, Xiaoping, Huddleston, Daniel, Ju, Yo-El, Kantarci, Kejal, Kotzbauer, Paul, Langley, Jason, Lim, Miranda, Lowe, Val, McLeland, Jenny, Miglis, Mitch, Mignot, Emmanuel, Neilson, Lee, Pelletier, Amelie, Postuma, Ron, Ross, Owen, Schenck, Carlos, Singer, Wolfgang, St Louis, Erik, Xiong, Chengjie

“…[...]what are the implications of negative SAA results? Because a substantial minority of isolated RBD cases are SLBD-negative,4 it is unknown if these cases…”
Get full text

Psychosocial implications of learning amyloid PET results in an observational cohort by Clark, Lindsay R., Erickson, Claire M., Chin, Nathaniel A., Basche, Kristin E., Ketchum, Fred B., Rosario, Hannah L., Peterson, Amanda J., Eveler, Marcella L., Johnson, Sterling C.

“…INTRODUCTION Information on the psychosocial impact of Alzheimer's disease (AD) biomarker testing in adults at risk of AD is needed to inform best practices…”
Get full text

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing by Ketchum, Fred B., Chin, Nathaniel A., Grill, Joshua, Gleason, Carey E., Erickson, Claire, Clark, Lindsay R., Paulsen, Jane S., Kind, Amy J.H.

“…Alzheimer's disease (AD) begins with an asymptomatic “preclinical” phase, in which abnormal biomarkers indicate risk for developing cognitive impairment…”
Get full text

Anticipated Psychological or Behavioral Reactions to Learning Alzheimer Biomarker Results: Associations With Contextual Factors by Clark, Lindsay R, Erickson, Claire M, Chin, Nathaniel A, Basche, Kristin E, Jonaitis, Erin M, Ketchum, Fred B, Gleason, Carey E

“…As Alzheimer disease (AD) biomarker testing becomes more widely available, adults may opt to learn results. Considering potential reactions to learning…”
Get full text

Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers by Ketchum, Fred B, Erickson, Claire M, Basche, Kristin E, Chin, Nathaniel A, Rosario, Hannah L, Johnson, Sterling C, Clark, Lindsay R

“…Recommendations for communicating Alzheimer's disease (AD) biomarkers include pre-disclosure participant education and counseling, to allow individuals to make…”
Get more information

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society by Erickson, Claire M., Clark, Lindsay R., Ketchum, Fred B., Chin, Nathaniel A., Gleason, Carey E., Largent, Emily A.

“…Disclosure of Alzheimer's disease (AD) biomarkers to cognitively unimpaired adults are currently conducted only in research settings. Yet, US Food and Drug…”
Get full text

Securing Opportunities for the Disadvantaged, or Medicalization Through the Back Door? by Ketchum, Fred B., Repantis, Dimitris

Get full text

Cardiology clinic patient attitudes toward and potential personal utility of genetic testing: Findings from a unique multiracial clinical sample by Erickson, Claire M., Clark, Lindsay R., Umucu, Emre, Vo, Nhi H., Volgman, Annabelle Santos, Chin, Nathaniel A., Ketchum, Fred B., Jones, Carolyn H., Gleason, Carey E., Aggarwal, Neelum T.

“…As more is understood about the hereditary nature of disease risk, the utility of genetic testing within cardiovascular medicine is increasingly being…”
Get full text

Rethinking "Cognitive" Enhancement: The Ethical Stakes of User Perspectives by Ketchum, Fred B.

“…AJOB Neuroscience Rethinking "Cognitive" Enhancement: The Ethical Stakes of User Perspectives…”
Get full text

Beyond psychological well‐being and behavior change: Participant experience and evaluation of an AD biomarker disclosure and lifestyle counseling protocol by Erickson, Claire M, Basche, Kristin E, Chin, Nathaniel A., Ketchum, Fred B, Clark, Lindsay R.

“…Background Earlier detection and improved accessibility of testing means more adults may learn their Alzheimer’s biomarker results. Incorporating feedback from…”
Get full text

Concerns with the new biological research criteria for synucleinopathy by Ketchum, Fred B, Chin, Nathaniel A

Get full text

African Americans' intentions to share their Alzheimer’s preclinical biomarker results with loved ones in a hypothetical vignette: the importance of support persons by Ketchum, Fred B, Erickson, Claire M, Chin, Nathaniel A., Gleason, Carey E., Clark, Lindsay R.

“…Background Literature on factors influencing the decision to enroll in Alzheimer’s biomarker research increasingly indicates that study partners are important…”
Get full text

Impact of learning amyloid PET results on test‐related distress and concern about dementia in a cognitively unimpaired observational cohort by Clark, Lindsay R., Chin, Nathaniel A., Erickson, Claire M, Johnson, Sterling C, Basche, Kristin E, Rosario, Hannah, Ketchum, Fred B

“…Background As biomarker testing becomes more widely available, people will have opportunities to learn Alzheimer’s disease (AD) biomarker results. We developed…”
Get full text